Welcome to our dedicated page for Forian news (Ticker: FORA), a resource for investors and traders seeking the latest updates and insights on Forian stock.
Forian Inc (Nasdaq: FORA) delivers SaaS-powered data solutions for healthcare, life sciences, and emerging markets. This news hub provides investors and professionals with essential updates on operational developments, financial performance, and strategic initiatives.
Access curated press releases covering earnings disclosures, regulatory compliance updates, technology partnerships, and market expansion activities. Our repository enables efficient tracking of Forian's progress in data management innovation and clinical analytics leadership.
Key updates include product launch announcements, executive appointments, financial filings, and industry collaborations. Bookmark this page for centralized access to verified corporate communications that inform investment decisions and sector analysis.
Forian Inc. (Nasdaq: FORA) reported a 37% year-over-year revenue growth in Q4 2022, totaling $7.9 million, with healthcare information revenue increasing 64%. The company reduced its net loss to $3.6 million or $0.11 per share, down from $8.0 million in Q4 2021. For the full year, total revenue reached $28.0 million, a 66% increase from 2021. Forian divested BioTrack for $30 million in February 2023, enhancing its balance sheet. The company expects 25% to 37% revenue growth in healthcare information in 2023, aiming for positive adjusted EBITDA in the second half of the year.
Forian Inc. (Nasdaq: FORA) announced it will release its fourth quarter and full year 2022 financial results on March 27, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. (ET) the same day. Investors can register for the call and access the webcast live on the company’s website. Forian provides data science-driven information and analytics solutions to healthcare and life sciences sectors, focusing on optimizing operational and financial performance for its clients. Forward-looking statements highlight potential risks and uncertainties that may affect future performance, suggesting caution in reliance on these projections.
